A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Completed · Phase 1
Conditions studied: Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
In brief
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors
Key facts
- Study ID
- NCT03775850
- Run by
- Evelo Biosciences, Inc.
- People needed
- 69
- Starts
- 2018-12-19
- Expected to finish
- 2021-10-31
- Last updated by the study team
- 2023-03-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Rogers, Arkansas, United States
- Florida Cancer Specialists — Sarasota, Florida, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Tennessee Oncology, PLLC — Chattanooga, Tennessee, United States
- Tennessee Oncology — Nashville, Tennessee, United States
- Centre de Recherche du CHUM — Montreal, Quebec, Canada
- Jewish General Hospital — Montreal, Quebec, Canada
- CHU de Québec - Université Laval — Québec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.